The scope of the Divestment Business is as follows:
The lactase manufacturing facility in the Tianjin Economic – Technological and Development Area, China (the "Lactase Plant") where [proportion] the Parties’ current production of the NOLA® bifido lactase products (“the NOLA products”) and the Saphera® bifido lactase products takes place. The Lactase Plant includes buildings, equipment and machinery, warehouse capacity and all required regulatory approvals and permits necessary to produce the NOLA products and prepare the Ha-Lactase™ yeast lactase products for distribution;
a worldwide, irrevocable, perpetual, royalty-free licence to the proprietary production strain and the production guide which will include all relevant production know-how needed to operate the Lactase Plant to produce the NOLA products;
the rights to develop, improve, manufacture and distribute the NOLA products, and the worldwide right to distribute the Ha-Lactase™ yeast lactase products and associated intellectual property rights and all required regulatory clearances, registrations and authorisations;
trade secrets, confidential know-how, confidential customer data, or other confidential information used exclusively or predominantly in the commercialisation of lactase;
the G2 collaboration agreement and all associated intellectual property rights needed to develop a G2 Lactase for manufacture within [time period];
the right to develop, manufacture and distribute a further lactase pipeline product, including all associated intellectual property rights;
a number of employees working in relation to the manufacture and distribution of lactase, including R&D employees;
the assignment or novation of (i) supply contracts, (ii) distribution agreements; and (iii) customer contracts related to lactase; and (i) transitional arrangements allowing the Divestment Business to benefit from equivalent arrangements equivalent to those that the Parties have in place for the supply of products and services for a period of 12 months.